We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Recent enforcement actions against two devicemakers indicate that the FDA is keeping a close watch on marketing efforts, particularly if they tout products for uncleared indications.
Independent third-party inspections could begin next month, and if the program is successful, the FDA will resume full-scale facility inspections, according to David Feigal, director of the Center for Devices and Radiological Health.